Sierra Oncology Inc (NASDAQ:SRRA) – Stock analysts at Jefferies Financial Group boosted their Q2 2019 earnings per share (EPS) estimates for Sierra Oncology in a research note issued to investors on Monday, May 13th. Jefferies Financial Group analyst M. Raycroft now anticipates that the biotechnology company will post earnings per share of ($0.19) for the quarter, up from their prior estimate of ($0.23). Jefferies Financial Group also issued estimates for Sierra Oncology’s Q3 2019 earnings at ($0.25) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($0.90) EPS, FY2020 earnings at ($1.01) EPS, FY2021 earnings at ($0.74) EPS, FY2022 earnings at ($0.49) EPS and FY2023 earnings at $0.27 EPS.
A number of other research analysts have also commented on the company. Zacks Investment Research raised Sierra Oncology from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Tuesday. Wedbush reaffirmed an “outperform” rating on shares of Sierra Oncology in a report on Thursday, February 28th.
Shares of NASDAQ SRRA opened at $1.43 on Thursday. The company has a current ratio of 13.07, a quick ratio of 13.07 and a debt-to-equity ratio of 0.06. Sierra Oncology has a one year low of $1.05 and a one year high of $3.70. The firm has a market capitalization of $106.81 million, a price-to-earnings ratio of -1.91 and a beta of 1.70.
Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04.
Hedge funds and other institutional investors have recently modified their holdings of the business. Brookstone Capital Management acquired a new stake in shares of Sierra Oncology during the 1st quarter worth $28,000. Virtu Financial LLC acquired a new stake in shares of Sierra Oncology during the 1st quarter worth $32,000. Blair William & Co. IL grew its holdings in shares of Sierra Oncology by 73.3% during the 1st quarter. Blair William & Co. IL now owns 29,319 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 12,400 shares in the last quarter. Hikari Power Ltd acquired a new stake in shares of Sierra Oncology during the 4th quarter worth $330,000. Finally, Acadian Asset Management LLC grew its holdings in shares of Sierra Oncology by 5.4% during the 4th quarter. Acadian Asset Management LLC now owns 407,105 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 20,754 shares in the last quarter. 64.56% of the stock is currently owned by hedge funds and other institutional investors.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Further Reading: Can systematic risk be avoided?
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.